Who We Are
A medtech leader with a robust pipeline of novel products for respiratory, asthma, cluster headache, wound care and skin care markets globally. Our patent-protected methodologies combine innovative biomedical, mechanical and chemical engineering, IoT and AI technologies to create first mover solutions in multiple mass markets. Our mission is to save lives, and to improve quality of life.
The Kwivik Leadership Team is comprised of Fortune 100 Management, SAB Members and Noteworthy Investors, including Private Equity and Venture Capital. With well in excess of 200 years combined experience in medical devices, technology, engineering, product development, commercialization and financial markets, the team is well positioned to realize Kwivik's vision and mission of hypergrowth through innovation and relentless execution, while serving our communities and saving lives.
Products and Customers
We are a customer facing organization, and we serve Consumer, Education, Commercial and Government customers globally. We a pre-IPO medical technology company with a robust product pipeline of at least 12 novel, proprietary blockbuster products in our Therapeutics catalog. In addition, our Covid19 catalog brings together lifesaving solutions in one place as a single-source solution, as we work to #flatten the curve.
Our total available market for all our products combined is a remarkable $1.06 Trillion USD. We develop and market innovative emergency medical and respiratory solutions in the areas of asthma, first aid, pre-responder emergency, cluster headaches, wound care and skin care. We own numerous issued, pending and provisional patents related to our groundbreaking products and technologies. One of the novel approaches incorporated in our oxygen platform is a unique, proprietary technology: Medically pure (USP) oxygen is created instantly when needed from a catalytic reaction of two dry, inert proprietary powders inside specially designed dispensers made of lightweight, usually thermoplastic, materials.